NCT06873789

A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label, Multicenter Study of INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.

Conditions

• Solid Tumors
• Advanced Solid Tumors
• Metastatic Solid Tumors

Interventions

Type	Name	Description
DRUG	INCB177054	INCB177054 will be administered at protocol defined dose.
DRUG	Retifanlimab	Retifanlimab will be administered at protocol defined dose.

Timeline

• Start date: 2025-06-30
• Primary completion: 2026-05-08
• Completion: 2026-05-08
• First posted: 2025-03-13
• Last updated: 2026-03-25

Locations

9 sites across 1 country: United States

Regulatory

• FDA-regulated drug study